Alnylam Pharmaceuticals | ALNY - Trade Creditors


Alnylam Pharmaceuticals reported $126.63M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 12.25M 1.34M Mar/2026
Agios Pharmaceuticals USD 13.75M 4.61M Mar/2026
Alnylam Pharmaceuticals USD 126.63M 10.91M Mar/2026
Amgen USD 19.52B 1.37B Mar/2026
Arrowhead Research USD 30.75M 2.19M Mar/2026
BioCryst Pharmaceuticals USD 10.96M 4.87M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Incyte USD 228.62M 1.41B Mar/2026
Ionis Pharmaceuticals USD 26.03M 2.05M Mar/2026
Moderna USD 161M 156M Mar/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novartis USD 4.46B 99M Dec/2025
PTC Therapeutics USD 25.48M 20M Mar/2026
Regeneron Pharmaceuticals USD 1.03B 4.81B Mar/2026
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sanofi EUR 22.93B 2.89B Dec/2025
Sarepta Therapeutics USD 70.38M 210.46M Mar/2026
Takeda JPY 491.34B 23.75B Mar/2026
Tectonic Therapeutic USD 2.55M 1.46M Mar/2026
Ultragenyx Pharmaceutical USD 42M 11M Mar/2026
Vertex Pharmaceuticals USD 3.47B 40.6M Mar/2026
Xencor USD 7.92M 2.91M Mar/2026